Topics:
Radiation Oncology • Thoracic Malignancies • Medical Oncology • Immunotherapy • Non-small cell lung cancer
Would you ever consider definitive thoracic RT with concurrent immunotherapy in Stage III NSCLC?
I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clinical trial?
Answer from: Radiation Oncologist at Academic Institution
Generally speaking in my opinion, concurrent chemoradiation with a platinum drug doublet remains standard of care outside of clinical trials. Definitive chemoradiation in stage III lung cancer is considered a curative regimen despite the risks of local recurrence (around 30%) and distant mets. Bear ...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
I completely agree with Dr. @Ronald C. McGarry that the appropriate setting for understanding the interaction between the standard of care for stage III lung cancer (definitive CRT then consolidation IO) and the addition of a novel concurrent agent [IO] to the CRT is in a trial setting. We are curre...